Reiki Therapy - an Intervention in Hematology/Oncology Cancer Patients Hospitalized

Reiki Therapy - an Intervention in Hematology/Oncology Cancer Patients Hospitalized in an Inpatient Setting - a Pilot Study.

Researchers are trying to determine if offering and providing reiki therapy in hospitalized hematology/oncology cancer subjects has any effects on symptoms and feeling during the subjects hospital stay.

Study Overview

• Status: Withdrawn
• Conditions: Cancer
• Intervention / Treatment: Other: Reiki Therapy

Detailed Description

Primary Aim:

The primary aim of this study is to evaluate the feasibility of offering and providing Reiki Therapy in hospitalized hematology/oncology cancer patients. The intervention should not - interfere with the medical management of the participants. The investigators hypothesize that Reiki Sessions will be successfully integrated into conventional care of hospitalized cancer patients.

Secondary Aim:

The secondary aim is to evaluate the patient reported outcomes of their symptoms (pain, fatigue, anxiety) and feelings (happy, energetic, relaxed, and calm) before and after Reiki Therapy. The investigators' hypothesis is that there will be improvement of patients' symptoms/feelings score after the Reiki Therapy.

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic in Rochester

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Hospitalized hematology-oncology patients age 18 - 80
• Able to speak English and complete surveys
• Able to read, understand and sign inform consent.

Exclusion Criteria:

• Patient unwilling for reiki therapy.
• Unable to give written consent.
• Already having received or receiving other reiki treatment.
• Pregnant women. (As verbalized by participant)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Hospitalized hematology/oncology cancer subjects; Hospitalized hematology/oncology cancer will participate in Reiki Therapy	Other: Reiki Therapy; Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in pain pain symptoms	Measured using a numeric rating scale, where 0 is not at all and 10 is unbearable	Baseline, approximately 2 hours
Change in fatigue symptoms	Measured using a numeric rating scale, where 0 is not at all and 10 is unbearable	Baseline, approximately 2 hours
Change in anxiety symptoms	Measured using a numeric rating scale, where 0 is not at all and 10 is unbearable	Baseline, approximately 2 hours
Change in feeling happy	Measured using a numeric rating scale, where 0 is best possible and 10 is worst possible	Baseline, approximately 2 hours
Change in feeling energized	Measured using a numeric rating scale, where 0 is best possible and 10 is worst possible	Baseline, approximately 2 hours
Change in feeling relaxed	Measured using a numeric rating scale, where 0 is best possible and 10 is worst possible	Baseline, approximately 2 hours
Change in feeling calm	Measured using a numeric rating scale, where 0 is best possible and 10 is worst possible	Baseline, approximately 2 hours

Collaborators and Investigators

• Sponsor: Mayo Clinic

Publications and helpful links

Helpful Links

• Mayo Clinic Clinical Trials

Study record dates

Study Major Dates

• Study Start (Actual): July 10, 2019
• Primary Completion (Actual): April 1, 2021
• Study Completion (Actual): April 1, 2021

Study Registration Dates

• First Submitted: May 9, 2019
• First Submitted That Met QC Criteria: May 9, 2019
• First Posted (Actual): May 13, 2019

Study Record Updates

• Last Update Posted (Actual): May 3, 2021
• Last Update Submitted That Met QC Criteria: April 28, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: 19-000456

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No